Navigation Links
Glass Lewis Recommends Arrow Shareholders Vote on the White Proxy Card for Merger With Teleflex and for Current Board of Directors at Arrow Annual Meeting
Date:9/10/2007

Says Current Board is 'Best Suited' to Conclude Merger and Manage Company

Company Announces Expiration of Hart-Scott-Rodino Waiting Period

READING, Pa., Sept. 10 /PRNewswire-FirstCall/ -- Arrow International, Inc. (Nasdaq: ARRO), a leading global provider of catheter-based access and therapeutic products for critical and cardiac care, reported that Glass, Lewis & Co., a leading proxy advisory firm, is advising its clients to approve Arrow's planned $45.50 merger with Teleflex Incorporated (NYSE: TFX) and vote on the WHITE proxy card to adopt the merger agreement and in favor of all of Arrow's director nominees at Arrow's upcoming Annual Meeting on September 20, 2007. Shareholders of record on August 7, 2007 are entitled to vote in person or by proxy at the Meeting.

In its recommendation dated September 7, 2007, Glass, Lewis stated, "We make this recommendation knowing that the current directors have shown great resolve to act in shareholder's interests during a period of executive and director turnover. In our opinion, we believe that the incumbent directors are best suited to manage the agreement to closure or to oversee the business in the case that the agreement is not approved by shareholders."*

R. James Macaleer, Chairman of the Board of Arrow International, Inc. said, "We are pleased that Glass, Lewis has advised its clients who are Arrow shareholders to vote for the $45.50 per share Teleflex merger and to support the election of the current Arrow Board. We encourage all shareholders to sign and return their WHITE proxy card today and to ignore the blue proxy cards from the McNeil Trust."

Arrow also announced the expiration of the waiting period required under the Hart-Scott-Rodino Antitrust Improvements Act in connection with the definitive agreement under which Teleflex will acquire Arrow in an all cash transaction valued at approximately $2 billion. There are no additional regulatory requirements that are conditions to consummating the transaction.

With this regulatory matter satisfied, the companies now expect the transaction to close shortly following the receipt of approval of a majority of the votes cast by all Arrow shareholders who are entitled to vote and who are present in person or by proxy at the Arrow Annual Meeting on September 20, 2007.

* Permission to use quotation from Glass, Lewis was neither sought or

obtained.

About Arrow:

Arrow develops, manufactures and markets a broad range of clinically advanced, disposable catheters and related products for critical and cardiac care. The company's products are used primarily by anesthesiologists, critical care specialists, surgeons, emergency and trauma physicians, cardiologists, interventional radiologists and other healthcare providers. Arrow's news releases and other company information can be found on the World Wide Web at http://www.arrowintl.com. Arrow's common stock trades on the NASDAQ Global Select Market SM under the symbol ARRO.

Caution Concerning Forward-looking information:

This press release contains forward-looking statements, including the anticipated timing for closing of the transaction. A further description of these risks and uncertainties and other important factors that could cause actual results to differ materially from Arrow's expectations can be found Arrow's Annual Report on Form 10-K, as amended and in Arrow's other filings with the SEC. The expectations and assumptions reflected in such forward looking statements may prove incorrect. Arrow does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise.

Additional Information

In connection with the proposed acquisition of Arrow by Teleflex Incorporated and Arrow's 2007 Annual Meeting of Shareholders, Arrow filed a definitive proxy statement with the SEC, on August 24, 2007 and will be filing other documents with the SEC. Prior to the Annual Meeting, Arrow will furnish the definitive proxy statement to its shareholders, together with a WHITE proxy card. Arrow shareholders are strongly advised to carefully read Arrow's definitive proxy statement. Shareholders may obtain the definitive proxy statement on file with the SEC and any other documents filed by Arrow with the SEC for free at the internet website maintained by the SEC at http://www.sec.gov. Shareholders will be able to obtain free copies of the definitive proxy statement and any amendments and supplements to the definitive proxy statement at Arrow's website at http://www.arrowintl.com or by writing to Arrow International, Inc., 2400 Bernville Road, Reading, Pennsylvania 19605. In addition, copies of Arrow's proxy materials may be requested by contacting our proxy solicitor, Morrow & Co. at (800) 662-5200 toll-free or by writing to Morrow & Co., 470 West Avenue, Stamford, CT 06902. Arrow and its directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Additional information regarding the names, affiliations and interests of individuals who are participants in the solicitation of proxies of Arrow's shareholders is available in Arrow's definitive proxy statement filed with the SEC on August 24, 2007.


'/>"/>
SOURCE Arrow International, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Short Glasses Make You Drink More
2. Over indulgence more so when intake is in short glasses
3. A Glass, Half Filled With Water Is Half Full Or Half Empty?
4. Sunglasses Can Really Pull a Fast One on the Biological Clock, and Set a Lag in the Build Up Of Jet Lag
5. Watch Out! Eye Glass Related Injuries On The Rise
6. Efforts To Replace Reading Glasses Are In View
7. Metallic and Glass Objects Retreived from Womens Stomach
8. A sty in Actress Konkona Sharma Disrupts the Shooting of Bi- Lingual movie Sunglass
9. A Glass of Orange Juice To Keep Recurrence Of Kidney Stones At Bay
10. Cataract Surgery to Eliminate Reading Glasses?
11. Quest for an hour glass figure results in rise of eating disorders by the hour
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2016)... Cary, North Carolina (PRWEB) , ... May 29, 2016 , ... ... KP-400L wide jaw clipper that has been available via Amazon.com. This new ... who have thick nails. , The jaw opening is approximately 4mm and the actual ...
(Date:5/29/2016)... ... May 29, 2016 , ... "With 30 unique self-animating ... user control the style of their project," said Christina Austin - CEO of Pixel ... web-themed intros created exclusively for use in Final Cut Pro X. Pixel Film Studios’ ...
(Date:5/28/2016)... ... 2016 , ... "Color Grading media can be time consuming but with FCPX ... said Christina Austin - CEO of Pixel Film Studios. , With the FCPX ... color grades to their footage. A LUT is a Lookup Table that contains a ...
(Date:5/28/2016)... ... ... and a half of planning the Multiple Pathways of Recovery Conference , CCAR is ... was held May 2 -4, 2016 at the Mystic Marriott Hotel & Spa . ... many pathways individuals use to get into and sustain their recovery. Pathways of recovery ...
(Date:5/27/2016)... Angeles, CA (PRWEB) , ... May 27, 2016 , ... ... of Health, so it is not surprising that bariatric surgery has received increased attention ... Business Journal explains. Of course, when it comes to weight loss, most people are ...
Breaking Medicine News(10 mins):
(Date:5/30/2016)... India , May 30, 2016 /PRNewswire/ ... market research report "Healthcare Biometrics Market by ... (Signature, Voice)), Multifactor, Multimodal), Application (Workforce Management), ... Forecast to 2021", published by MarketsandMarkets, the ... Million by 2021 from USD 1,182.6 Million ...
(Date:5/30/2016)... 2016 The global  parenteral ... billion by 2024, according to a new report ... rate, the growing malnutrition coupled with the prevalence ... tract diseases are expected to boost the market ... http://photos.prnewswire.com/prnh/20150105/723757 ) , The ...
(Date:5/30/2016)... 30, 2016 - DCGI grants limited approval ... Buerger,s disease - Stempeucel® becomes 5th off-the-shelf Stem cell ... world - Buerger,s Disease (also known as Thromboangiitis Obliterans) ... and Globally - Prevalence of Buerger,s Disease is ... 2 per 10,000 persons in the European Community & ...
Breaking Medicine Technology: